DETERMINATION OF PYRIMETHAMINE IN HUMAN PLASMA AFTER ADMINISTRATION OF FANSIDAR OR FANSIDAR-MEFLOQUINE BY MEANS OF HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH FLUORESCENCE DETECTIONTIMM U; WEIDEKAMM E.1982; J. CHROMATOGR.; ISSN 0021-9673; NLD; DA. 1982; VOL. 230; NO 1; PP. 107-114; BIBL. 16 REF.Article

RAMAN AND INFRARED SPECTROSCOPIC STUDY OF GRAMICIDIN A CONFORMATIONSIQBAL Z; WEIDEKAMM E.1980; ARCH. BIOCHEM. BIOPHYS.; USA; DA. 1980; VOL. 202; NO 2; PP. 639-649; BIBL. 22 REF.Article

INFRARED SPECTROSCOPY OF BIOMEMBRANE CHANNEL: GRAMICIDIN AIQBAL Z; WEIDEKAMM E.1979; INFRARED PHYS.; GBR; DA. 1979; VOL. 19; NO 3-4; PP. 435-479; BIBL. 9 REF.Conference Paper

PRE-RESONANCE RAMAN SPECTRA AND CONFORMATIONS OF NYSTATIN IN POWDER, SOLUTION AND PHOSPHOLIPID-CHOLESTEROL MULTILAYERSIQBAL Z; WEIDEKAMM E.1979; BIOCHIM. BIOPHYS. ACTA; NLD; DA. 1979; VOL. 555; NO 3; PP. 426-435; BIBL. 14 REF.Article

EXTRACTION AND LOCALIZATION OF A (CA²⁺+MG²⁺) STIMULATED ATPASE IN HUMAN ERYTHROCYTE SPECTRIN.WEIDEKAMM E; BRDICZKA D.1975; BIOCHIM. BIOPHYS. ACTA; PAYS-BAS; DA. 1975; VOL. 401; NO 1; PP. 51-58; BIBL. 22 REF.Article

PHOSPHOLIPID COMPOSITION OF HUMAN ERYTHROCYTE SPECTRIN.WEIDEKAMM E; BRDICZKA B; WILDERMUTH M et al.1978; MOLEC. BIOL. REP.; NETHERL.; DA. 1978; VOL. 4; NO 1; PP. 25-28; BIBL. 37 REF.Article

LASER-RAMAN STUDY OF VALINOMYCIN-DOPED AND OMEGA -CD₃-LABELED PHOSPHATIDYLCHOLINE LIPOSOMES.WEIDEKAMM E; BAMBERG E; JANKO K et al.1978; ARCH. BIOCHEM. BIOPHYS.; U.S.A.; DA. 1978; VOL. 187; NO 2; PP. 339-345; BIBL. 28 REF.Article

BIOCHEMICAL CHARACTERIZATION OF SEGREGATED MEMBRANE VESICLES FROM HUMAN ERYTHROCYTES WITH INCREASED INTRACELLULAR CA²⁺.WEIDEKAMM E; BRDICZKA D; DI PAULI G et al.1977; ARCH. BIOCHEM. BIOPHYS.; U.S.A.; DA. 1977; VOL. 179; NO 2; PP. 486-494; BIBL. 32 REF.Article

Penetration of fleroxacin into human and animal tissuesPORTMANN, R; WEIDEKAMM, E.Chemotherapy (Basel). 1992, Vol 38, Num 3, pp 145-149, issn 0009-3157Article

PLASMA CONCENTRATIONS OF PYRIMETHAMINE AND SULFADOXINE AND EVALUATION OF PHARMACOKINETIC DATA BY COMPUTERIZED CURVE FITTINGWEIDEKAMM E; PLOZZA NOTTEBROCK H; FORGO I et al.1982; BULL. W.H.O.; ISSN 0366-4996; CHE; DA. 1982; VOL. 60; NO 1; PP. 115-122; ABS. FRE; BIBL. 9 REF.Article

A new trifluorinated quinolone: RO 23-6240 (AM 833)WEIDEKAMM, E; STOCKEL, K; DELL, D et al.Drugs under experimental and clinical research. 1987, Vol 13, Num 2, pp 85-90, issn 0378-6501Article

Penetration of fleroxacin into body tissues and fluidsWEIDEKAMM, E; PORTMANN, R.The American journal of medicine. 1993, Vol 94, Num 3A, pp 3A.75S-3A.80S, issn 0002-9343Conference Paper

Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef^®WEIDEKAMM, E; SCHWARTZ, D. E; DUBACH, U. C et al.Chemotherapy (Basel). 1987, Vol 33, Num 4, pp 259-265, issn 0009-3157Article

Lack of bioequivalence of a generic mefloquine tablet with the standard productWEIDEKAMM, E; RÜSING, G; CAPLAIN, H et al.European journal of clinical pharmacology. 1998, Vol 54, Num 8, pp 615-619, issn 0031-6970Article

Penetration of fleroxacin into breast milk and pharmacokinetics in lactating womenDAN, M; WEIDEKAMM, E; SAGIV, R et al.Antimicrobial agents and chemotherapy. 1993, Vol 37, Num 2, pp 293-296, issn 0066-4804Article

Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic β-lactam, in humansWEIDEKAMM, E; STOECKEL, K; EGGER, H.-J et al.Antimicrobial agents and chemotherapy. 1984, Vol 26, Num 6, pp 898-902, issn 0066-4804Article

Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysisSTUCK, A. E; FREY, F. J; HEIZMANN, P et al.Antimicrobial agents and chemotherapy. 1989, Vol 33, Num 3, pp 373-381, issn 0066-4804Article

Multiple-dose pharmacokinetics of the antimalarial drug fansimel (pyrimethamine+sulfadoxine+mefloquine) in healthy subjectsSCHWARTZ, D. E; WEIDEKAMM, E; MIMICA, I et al.Chemotherapy (Basel). 1987, Vol 33, Num 1, pp 1-8, issn 0009-3157Article

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsSCHÜLLER, J; CASSIDY, J; DUMONT, E et al.Cancer chemotherapy and pharmacology. 2000, Vol 45, Num 4, pp 291-297, issn 0344-5704Article

Single-dose pharmacokinetics of oral fleroxacin in bacteremic patientsSCHRENZEL, J; CERRUTI, F; HERRMANN, M et al.Antimicrobial agents and chemotherapy. 1994, Vol 38, Num 6, pp 1219-1224, issn 0066-4804Article

Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patientsHAYTON, W. L; VLAHOV, V; BACRACHEVA, N et al.Antimicrobial agents and chemotherapy. 1990, Vol 34, Num 12, pp 2375-2380, issn 0066-4804, 6 p.Article

Pharmacokinetics of tenoxicam in patients with impaired renal functionHORBER, F. F; GUENTERT, T. W; WEIDEKAMM, E et al.European journal of clinical pharmacology. 1986, Vol 29, Num 6, pp 697-701, issn 0031-6970Article

Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolitesTWELVES, C; GLYNNE-JONES, R; CASSIDY, J et al.Clinical cancer research. 1999, Vol 5, Num 7, pp 1696-1702, issn 1078-0432Article

Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patientsREIGNER, B; CLIVE, S; WEIDEKAMM, E et al.Cancer chemotherapy and pharmacology. 1999, Vol 43, Num 4, pp 309-315, issn 0344-5704Article

Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patientsREIGNER, B; VERWEIJ, J; OSTERWALDER, B et al.Clinical cancer research. 1998, Vol 4, Num 4, pp 941-948, issn 1078-0432Article